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Abstract
The clinical and molecular epidemiology of Staphylococcus aureus disease has changed considerably over the past two decades, particularly
with the emergence and spread of community-associated methicillin-resistant S. aureus (CA-MRSA) clones. Indeed, some of the ﬁrst global
descriptions of CA-MRSA were from remote indigenous communities in Western Australia, and from Paciﬁc Peoples in New Zealand. The
epidemiology of S. aureus infections in the South West Paciﬁc has several unique features, largely because of the relative geographical
isolation and unique indigenous communities residing in this region. In particular, a number of distinct CA-MRSA clones circulate in Australia
and New Zealand, such as sequence type (ST) 93 methicillin-resistant S. aureus (MRSA) (Queensland clone) and clonal complex 75 S. aureus
(Staphylococcus argenteus) in Australia, and ST30 MRSA (Southwest Paciﬁc clone) in New Zealand. In addition, there is a disproportionate
burden of S. aureus disease in indigenous paediatric populations, particularly in remote Aboriginal communities in Australia, and in Paciﬁc
Peoples and Maori in New Zealand. In this review, we provide a contemporary overview of the clinical and molecular epidemiology of
S. aureus disease in the South West Paciﬁc region, with a particular focus on features distinct to this region.
Keywords: Epidemiology, indigenous health, methicillin-resistant Staphylococcus aureus, Staphylococcus aureus
Article published online: 31 May 2014
Clin Microbiol Infect 2014; 20: 597–604
Corresponding author: G. R. Nimmo, Pathology Queensland
Central Laboratory, Brisbane, Qld, Australia
E-mail: graeme.nimmo@health.qld.gov.a
Introduction
Staphylococcus aureus is a major human pathogen, and infec-
tions with S. aureus are associated with considerable morbidity
and mortality [1–3]. The clinical and molecular epidemiology of
S. aureus infections has changed dramatically over the past two
decades. Remarkably, the ﬁrst indication of the change to
come was a report from Western Australia of the emergence
of community-associated methicillin-resistant S. aureus
(CA-MRSA) causing infections in remote indigenous commu-
nities [4]. The emergence and epidemic spread of successful
CA-MRSA clones in many parts of the world followed, most
notably the USA300 clone in North America [5]. Initial reports
of CA-MRSA described several distinct features, including the
emergence of these strains in patients without traditional
epidemiological risk factors for methicillin-resistant S. aureus
(MRSA) infection, and low rates of resistance to non-b-lactam
antimicrobials. Speciﬁcally, patients with CA-MRSA infections
were younger, had minimal comorbid illness and lacked prior
healthcare contact as compared with patients with infections
caused by healthcare-associated MRSA (HA-MRSA) strains
[5,6]. More recent studies suggest further changes in the
epidemiology of S. aureus disease, with the emergence and
spread of CA-MRSA clones in the healthcare setting [7].
However, although the changing epidemiology of S. aureus
disease in North America has been extensively characterized,
comparatively little is known about the epidemiology of
S. aureus disease in the southern hemisphere. It is of note
that the relative geographical isolation (both of and within)
Australia, New Zealand and the South Paciﬁc (collectively
referred to as the South West Paciﬁc) has resulted in the
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circulation of a diverse range of S. aureus strains [8,9].
Moreover, the epidemiology of S. aureus infections in the
South West Paciﬁc has distinct socio-demographic features as
compared with several other settings, with a disproportionate
burden of S. aureus disease in unique indigenous populations.
This review will describe the contemporary clinical and
molecular epidemiology of S. aureus disease in the South
West Paciﬁc, with a focus on those epidemiological charac-
teristics that are speciﬁc to this setting.
Clinical Epidemiology and Demographics of
S. aureus Disease in the South West Paciﬁc
Skin and soft tissue infections (SSTIs)
The most common clinical manifestation of S. aureus disease is
SSTI, and, as in other settings [10,11], recent studies have
described an increase in the incidence of SSTI in Australia and
New Zealand over the past decade [12–15]. For example, one
Australian study examined national hospitalization coding data,
and observed an increase in the rate of hospital admissions for
cutaneous abscesses from 46 per 100 000 population in 1999–
2000 to 62 per 100 000 population in 2007–2008, with the
highest incidence in the <5-year age group [12]. Utilizing an
expanded range of hospital discharge codes, another descrip-
tive study assessed trends in the incidence of serious S. aureus
disease across the New Zealand population between 2000 and
2011 [15]. These authors observed a signiﬁcant increase in
national rates of hospitalization for S. aureus skin infections,
from 81 per 100 000 population in 2000 to 140 per 100 000 in
2011 (p <0.001). Similarly, using laboratory-based surveillance,
a recent study from Auckland, New Zealand described a
signiﬁcant (p <0.001) increase in non-invasive S. aureus infec-
tions between 2001 and 2011, largely driven by commu-
nity-onset methicillin-sensitive S. aureus (MSSA) infections
[16].
In addition to rising rates of S. aureus SSTI, distinct
socio-demographic differences have been described for
S. aureus SSTI in the South West Paciﬁc, with a strikingly
disproportionate burden of disease in indigenous communities,
particularly in paediatric populations. A recent study of
S. aureus SSTI in New Zealand children found that Maoris
(indigenous New Zealanders) were twice as likely and Paciﬁc
Peoples almost three times as likely to be admitted to hospital
with S. aureus SSTI than European children [14]. Similarly, in
Australia, Aboriginal children were 12 times more likely to be
hospitalized with skin infections than non-Aboriginal children
in Western Australia [17], and Aborigines and Torres Straight
Islanders accounted for 37% of cases of infection, predomi-
nantly SSTI, in a Queensland study while constituting only 3.6%
of the population [18]. The underlying reasons for these
notable disparities are unclear, but contributory factors
probably include domestic overcrowding, factors related to
household hygiene, and delayed or inadequate access to
healthcare [13,14,16,17,19].
Data are scarce from regions other than Australia and New
Zealand, although a prospective study of skin disease in Fiji
[20] found that one-quarter of school-aged children (885/3462;
25.6%) had active impetigo, with S. aureus being isolated from
57% (323/563) of swabs.
Invasive S. aureus infections
S. aureus causes a spectrum of invasive infections, including
osteomyelitis, necrotizing pneumonia, and bloodstream infec-
tion. In particular, S. aureus bacteraemia (SAB) is associated
with considerable morbidity and mortality, with reported
global incidence rates varying between 14 and 41 per 100 000
population [2,21], although it should be noted that differences
in case ascertainment and study methodology limit compari-
sons between regions. To date, a number of population-based
studies of SAB in Australia, New Zealand and the South Paciﬁc
have been performed, with estimated overall annual SAB
incidence rates between 11 and 65 per 100 000 population
(Table 1). Similarly to S. aureus SSTI, signiﬁcant socio-demo-
graphic variation has been described in SAB incidence, with
rates being considerably higher in indigenous populations.
Notably, in one Australian study from the Northern Territory,
SAB incidence in the Aboriginal population was six times
higher than in the non-Aboriginal population, with the highest
reported SAB incidence rate to date (172 per 100 000
population) [19].
In Australia, concern that healthcare-associated SAB was
largely preventable led to the introduction of a national
programme to improve the hand hygiene compliance of
healthcare workers. Implementation of the programme in
2009–2010 was temporally associated with a reduction in SAB
rate [22]. Subsequently, data on rates of SAB associated with
Australian public hospitals have become publicly available [23],
predominantly as a performance marker for infection control
interventions. In 2012–2013, the overall national rate of SAB
was 0.9 per 10 000 patient-days, although differences in the
range and types of patient treated at each centre are likely to
contribute to varying rates between regions. Interestingly, the
national reported number of healthcare-associated SAB cases
decreased by 8% between 2010–2011 and 2012–2013, a trend
also seen in other geographical settings [10,24]. In keeping with
these ﬁndings, a recent study in Auckland, New Zealand also
observed a signiﬁcant decrease in invasive S. aureus infections
between 2001 and 2011 [16]. These authors suggested that
local measures to improve infection control practices, such as
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improvements in hand hygiene compliance and measures to
reduce intravascular device-related infections, may have con-
tributed to this observed decrease [16].
Antimicrobial Resistance Patterns of
S. aureus in the South West Paciﬁc
A number of national and international surveillance platforms
exist for monitoring antimicrobial resistance in S. aureus in the
South West Paciﬁc. These include: (i) the Regional Resistance
Programme, which monitors antimicrobial resistance in 12
Asia-Paciﬁc countries, including Australia and New Zealand
[25]; and (ii) systematic national surveillance programmes such
as those implemented by the Australian Group on Antimicro-
bial Resistance (AGAR) and the Institute of Environmental
Science and Research in New Zealand [26–28]. Data from such
surveys indicate that, as in other settings, antimicrobial
resistance patterns in S. aureus have changed in the South
West Paciﬁc over the past decade, predominantly because of
the emergence of CA-MRSA strains. For example, biennial
AGAR survey data showed a signiﬁcant increase in the
prevalence of clinical MRSA isolates in outpatients from
11.5% in 2000 to 17.9% in 2012 [28]. In comparison, the
proportion of MRSA in S. aureus isolates from hospital
inpatients remained stable between 2005 (31.9%) and 2011
(30.3%), although there were signiﬁcant inter-state differences
in MRSA prevalence [29]. It is of note that data from these
latter surveys showed a decreasing trend in hospital MRSA
resistance rates for many non-b-lactam antimicrobials, partic-
ularly erythromycin, tetracycline, co-trimoxazole, ciproﬂoxa-
cin, and gentamicin, suggesting an inﬁltration of
non-multiresistant CA-MRSA clones into the healthcare set-
ting and replacement of previously endemic healthcare-asso-
ciated clones [28].
Rates of MRSA are lower in New Zealand, with recent
aggregate national antimicrobial susceptibility data showing a
stable MRSA prevalence of c. 10% [30]. As in Australia, rates of
resistance in MRSA to many non-b-lactam antimicrobials,
speciﬁcally erythromycin, clindamycin, and ﬂuoroquinolones,
have declined over the past 5 years, again reﬂecting the
emergence of CA-MRSA clones in this setting [42]. Interest-
ingly, however, the rates of fusidic acid resistance in MRSA in
New Zealand have increased dramatically, from 12.1% in
2008 to 37.4% in 2012 [30]. This increase is likely to be
attributable to the rapid emergence of a sequence type (ST)5
MRSA clone in New Zealand (see below), which typically
shows resistance to fusidic acid [31]. Contemporary data on
resistance rates in MRSA in Australia and New Zealand are
shown in Table 2.
There are few studies on MRSA prevalence from other
countries in the South West Paciﬁc. However, one study from
Samoa found an MRSA prevalence of 17%, with the majority of
MRSA isolates (22/34; 64.7%) being resistant only to b-lactam
TABLE 1. Epidemiological studies of Staphylococcus aureus bacteraemia (SAB) in Australia and New Zealand
Location
[reference]
Time
period
Type of
study
No. of
SAB
cases
Age
group (s)
Overall
SAB incidence
(per 100 000
population)
SAB incidence
(per 100 000
population)
in indigenous
populations
Community-
onset (%)a
Crude 30-
day
case-
fatality
ratio (%)
MRSA
prevalence
(%)
Auckland and
Christchurch, NZ [65]
1996–1997 Prospective 424 Adults
(≥16 years)
41 Maori, 31; PP, 91 50 19 5
Auckland and
Christchurch, NZ [66]
1996–1997 Prospective 125 Children
(<16 years)
16.9 NR 70 3 6
Christchurch, NZ [67] 1998–2006 Retrospective 779 Adults and
children
21.5 Maori, 17.9; PP, 23.1 64 18 0.4
Australia,
multicentre [68]
1999–2002 Retrospective 3192 Adults and
children
35 NR 49 21b 27
Canberra, Australia [2] 2000–2008 Retrospective NR Adults and
children
26.3 NR NR NR NR
Alice Springs,
Australia [69]
2003–2006 Retrospective 125 Adults and
children
NR 160.7c NR 13d 21
Northern Territory,
Australia [19]
2006–2007 Prospective 110 Adults and
children
65 172 NR NR 25
Suva, Fiji [33] 2006–2007 Retrospective 128 Adults and
children
50.1 iTaukei, 66.2 NR NR 2.3
Australia and NZ,
multicentre [70]
2007–2008 Prospective 1994 Adults and
children
NR NR 60.8 20.6e 24.1
Australia,
multicentre [71]
2007–2010 Prospective 7539 Adults and
children
11.2 62.5 60.6 18.1f NR
MRSA, methicillin-resistant Staphylococcus aureus; NR, not reported; PP, Paciﬁc Peoples; NZ, New Zealand.
aIncludes community-onset healthcare-associated cases.
bBased on 30-day follow-up of 785 patients at two hospitals.
cReported rate of 8.1 per 100 000 in non-indigenous population.
dBased on 90-day follow-up.
eData available for 1865 patients.
fData available for 6916 patients.
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antimicrobials [32]. In addition, a recent study from Fiji [33]
found an MRSA prevalence of 6.2% (20/323) in S. aureus skin
isolates from children, with all 20 isolates being resistant only
to b-lactams and no more than one other class of antimicro-
bial.
Molecular Epidemiology of S. aureus in the
South West Paciﬁc
The relative geographical isolation and distinct indigenous
communities residing within the South West Paciﬁc have
contributed to the diverse nature of circulating S. aureus
strains in this region. Indeed, the earliest reported CA-MRSA
infections, caused by an ST8 CA-MRSA strain, were from
indigenous communities in the remote Kimberly region in
Western Australia [4]. Similarly, reports in the mid-1990s from
New Zealand suggested that an ST30 MRSA clone (colloquially
known as the ‘South West Paciﬁc’ clone) was responsible for
an increasing number of community-associated infections in
Paciﬁc peoples [34,35]. This section will review the major
contemporary S. aureus clones in the South West Paciﬁc, with
a speciﬁc focus on clones distinct to each geographical setting.
The standard nomenclature of multilocus ST (MLST) and
SCCmec typing will be used to describe MRSA clones (for
example, ST5-IV refers to an ST5 strain containing the type IV
SCCmec element).
Australia
Since 2008, the predominant CA-MRSA clone in Australia has
been the ST93-IV Queensland clone [36]. First identiﬁed in
2000 in a study in Ipswich in southeast Queensland [37], this
clone harbours the lukF-PV/lukS-PV (Panton–Valentine leukoci-
din (PVL)) genes, is typically susceptible to non-b-lactam
antimicrobials, and has successfully spread throughout Austra-
lia. A singleton by MLST, ST93-IV is associated with both skin
infections and severe invasive infections, such as necrotizing
pneumonia and osteomyelitis [38]. Interestingly, there have
been recent reports describing the emergence and transmis-
sion of this clone in other parts of the world, largely facilitated
by international travel [39,40]. Genomic analysis of nationally
representative ST93 isolates has revealed genetic diversity
within the ST93 clone [41,42], and more recent phylogenetic
data suggest that this clone emerged in Western Australia in
the 1970s, and acquired the mobile SCCmec-IV on at least two
occasions in the mid-1990s [43]. It is of note that, despite a
lack of known virulence-associated determinants as compared
with other CA-MRSA clones, a representative ST93 strain
(JKD6159) was shown to be signiﬁcantly more virulent than
other CA-MRSA clones (including USA300) in murine models
of skin infection and systemic sepsis [44]. The exact mecha-
nism(s) for this increased virulence potential is unclear,
although recent data suggest that increased production of
exotoxins, particularly a-haemolysin and phenol-soluble mod-
ulin a3, may have partially contributed to this observation
[43,45].
Another distinct clone that has emerged as a major cause of
community-onset S. aureus infections in Australia, speciﬁcally
in indigenous populations in the Northern Territory, is clonal
complex (CC)75 S. aureus. In one recent study, CC75
accounted for 8% of all MSSA isolates and 69% of MRSA
isolates recovered from skin lesions in Aboriginal children in
the Northern Territory, although it was rarely isolated from
patients with hospital-onset infections [46]. Phenotypically,
strains from this lineage are typically non-pigmented, and
genomic analysis of a representative CC75 strain (MSHR1132)
showed that this strain lacked an operon encoding the
carotenoid pigment staphyloxanthin [9]. Another key distin-
guishing genomic feature of this clone is the marked genetic
divergence from other S. aureus lineages, with c. 10% nucle-
otide diversity from other S. aureus lineages [9]. The differen-
tial phylogeny of CC75 has led to the suggestion that this clone
be renamed as a separate species, Staphylococcus argenteus
[9,46].
A number of other CA-MRSA clones are known to circulate
in Australia, with the six most common identiﬁed in an AGAR
survey in 2012 being (in decreasing order of prevalence):
ST93-IV, ST30-IV, ST1-IV, ST45-IV, ST78-IV, and ST5-IV [36].
In contrast to the diverse nature of CA-MRSA clones,
circulating HA-MRSA clones in Australia are more restricted:
ST239-III (also known as ‘Aus2/3 EMRSA’) has been endemic in
eastern Australia since the late 1970s [47,48], and was the
dominant HA-MRSA clone until recently, when it was replaced
by ST22-IV (also known as ‘EMRSA-15’) [29]. The latter ﬁrst
appeared in 2000, probably because of importation by
TABLE 2. Antimicrobial susceptibility patterns in methicil-
lin-resistant Staphylococcus aureus isolates in Australia and
New Zealand
Antimicrobial
Country [reference]; % resistant (number tested)
Australia—
community
isolates [28]
Australia—
hospital
isolates [29]
New Zealand—
hospital and
community
isolates [30]
Clindamycin 13.3 (510) 29.7 (713) 17.4 (7419)
Ciproﬂoxacin 37.5 (510) 66.9 (713) 24.3 (4923)
Co-trimoxazole 10.2 (510) 30.7 (713) 1.5 (7940)
Erythromycin 39.2 (510) 64.0 (713) 27.1 (7846)
Fusidic acid 5.1 (510) 4.0 (713) 37.4 (4794)
Gentamicin 9.4 (510) 30.4 (713) 4.2 (3687)
Mupirocin 1.6 (510) 1.0 (713) 9.5 (5142)
Tetracycline 14.5 (510) 33.5 (713) 2.4 (7090)
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overseas healthcare workers [49]. Of concern is the recent
identiﬁcation of PVL-positive ST22-IV as the cause of a
nosocomial outbreak in a neonatal intensive-care unit in
Sydney [50]. PVL-positive ST22-IV has successfully dissemi-
nated in both hospitals and the community in India [51], and
there are reports of outbreaks in both Europe and Japan [52].
New Zealand and Polynesia
For almost two decades, the predominant CA-MRSA clone
in New Zealand has been the South West Paciﬁc ST30-IV
clone [53]. First isolated in the Auckland community in 1992
from individuals who had contact with Western Samoa [34],
this clone emerged throughout the mid-1990s and early
2000s to become the major cause of CA-MRSA infections
throughout New Zealand, and it has subsequently been
reported from several other regions, including Europe and
North America [54]. Interestingly, a study of S. aureus skin
isolates from Samoa in 2007 [32] found that ST30-IV
constituted only 12% (4/34) of MRSA, with the three most
common MRSA clones being ST8-IV (USA300) (13/34; 29%),
ST93-IV (Queensland clone) (9/34; 26%), and ST1-IV MRSA
(9/34; 26%). Like other CA-MRSA clones, ST30-IV harbours
the lukF-PV/lukS-PV genes and is predominantly associated
with skin infections in otherwise healthy individuals, although
recent data suggest that ST30-IV is also responsible for a
sizeable proportion of MRSA infections in patients with prior
healthcare exposure [55]. Recent phylogenomic analysis
suggests that South West Paciﬁc ST30-IV may have emerged
independently from an ancestral CC30 clone in 1967,
although this study did not include isolates from New
Zealand or Samoa [56].
Since 2005, an ST5-IV clone has rapidly displaced ST30-IV as
the predominant CA-MRSA clone in New Zealand, accounting
for approximately half of all MRSA in a national period-prev-
alence survey in 2012 [26]. Although the underlying reasons
for the rapid and sustained emergence of this clone are
unclear, it is noteworthy that this clone typically shows
resistance to fusidic acid, and, in New Zealand, fusidic acid is
the recommended topical antimicrobial agent for the treat-
ment of impetigo [57]. Indeed, recent data suggest that
community prescriptions for fusidic acid have increased
signiﬁcantly in New Zealand over the past decade (Williamson
DA, in submission).
There are few data on the molecular epidemiology of
S. aureus infections from other regions in the South West
Paciﬁc, although a recent study from Fiji [33] found that CC1
MRSA accounted for all community MRSA isolates, and that
the most common MRSA types in the hospital setting were
ST239-III (14/36; 39%), CC1 (15/36; 42%), CC30 (5/36; 14%),
CC59 (1/36; 3%), and CC101 (1/36; 3%).
MSSA clones
Despite the majority of S. aureus disease in Australia and New
Zealand being caused by MSSA, relatively little is known about
the molecular epidemiology and population structure of MSSA
circulating in either country. However, a recent study of
community-onset S. aureus disease in Auckland children iden-
tiﬁed three predominant MSSA clones—CC1, CC121, and
CC30—that, together, accounted for approximately
two-thirds of MSSA isolates [58]. It is of note that the
prevalence of lukF-PV/lukS-PV genes in MSSA isolates was 56%, a
rate higher than that reported in a previous New Zealand
study, which detected the lukF-PV/lukS-PV genes in 37% of
disease-causing MSSA isolates [59]. In a recent Australian study
on community-onset S. aureus infections presenting to general
practices in south-eastern Australia [60], the MSSA population
consisted of 25 different strains, with the lukF-PV/lukS-PV genes
being detected in at least four clonal clusters and in one
singleton (CC1, CC20, CC121, CC30, and ST93). Three of the
PVL-positive lineages (CC1, CC30, and ST93) were also
identiﬁed in the CA-MRSA population. Among a collection of
105 MSSA isolates in Fiji, a diverse range of CCs were
detected, with the most common being CC5, CC7, CC14,
CC75, and CC121 [33].
Emerging MRSA clones in Australia and New Zealand
Over the past decade, a number of notable overseas
CA-MRSA clones have been detected in both Australia and
New Zealand. These include ST8-IV (USA300) [36,55], ST59-V
(‘Taiwan CA-MRSA’), and ST772-V (‘Bengal Bay clone’)
[36,55]. In addition, a recent New Zealand study described
the isolation of CC398 MRSA from nine patients [61] with two
distinct clusters: one attributable to CC398 isolates harbour-
ing lukF-PV/lukS-PV genes and associated with travel to South-
east Asia; and the other attributable to a ‘PVL-negative’ ST398
strain similar to the European livestock-associated CC398
lineage [62]. PVL-negative CC398 MRSA has recently been
reported from an individual in Australia [63], and has also been
detected in an Australian swine herd [64].
Conclusions
In summary, the clinical and molecular epidemiology of S. aureus
disease in the SouthWest Paciﬁc has changed considerably over
the past two decades. Important limitations of this review
include the paucity of data available from South West Paciﬁc
regions other than Australia and New Zealand, and the
comparative lack of data on the molecular epidemiology of
MSSA. Notable features include the emergence and dissemina-
tion of distinct CA-MRSA clones, particularly ST93-IV andCC75
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in Australia, and ST30-IV and fusidic acid-resistant ST5 in New
Zealand. Moreover, international travel has facilitated both the
exportation of these clones to other settings, and the impor-
tation of overseas MRSA clones into this relatively isolated
region. Of most concern, however, are observations of
increasing rates of S. aureus SSTI in both Australia and New
Zealand, particularly in indigenous paediatric populations.
Future work should aim to understand the factors driving this
trend, in order to inform speciﬁc strategies designed to reduce
the burden of staphylococcal disease in this region.
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